Nivolumab and ipilimumab for colorectal cancer
Colorectal Cancer

New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer

2025-01-31

  • Study

    Phase 3, multicenter, open-label, randomized clinical trial (CheckMate 8HW)
    Unresectable or metastatic colorectal cancer with MSI-H/dMMR status, across all treatment lines
    Nivolumab + ipilimumab vs. nivolumab

  • Efficacy

    mPFS: NR vs. 39.3 mos (nivolumab + ipilimumab vs. nivolumab) (HR: 0.62 [0.48-0.81], p=0.0003)

  • Safety

    Any grade AEs: 81% vs. 71%
    Grade ≥3 AEs: 22% vs. 14%
    Treatment-related deaths: 2 vs. 1 (nivolumab + ipilimumab vs. nivolumab)


    • Lancet 2025;405:383-395.

    Andre T,Elez E,Lenz HJ Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

    http://doi.org/10.1016/S0140-6736(24)02848-4

    Reviewed by Ulas D. Bayraktar, MD on Jan 31, 2025